A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1423 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Viokace | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1648 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna | Physicians Total Care, Inc. | Light-pink, biconvex round tablet | Oral route | Renin inhibitor | Renin |
1649 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna | Novartis Pharmaceuticals Corporation | Light-pink, biconvex round tablet | Oral route | Renin inhibitor | Renin |
1650 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekturna HCT | Novartis Pharmaceuticals Corporation | Biconvex, ovaloid film-coated tablets. | Oral route | Renin inhibitor | Renin |
1651 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Tekamlo | Novartis Pharmaceuticals Corporation | Tablets (aliskiren/amlodipine): 150 mg/5 mg, 150 mg/10 mg, 300 mg/5 mg, 300 mg/10 mg | Oral route | Renin inhibitor | Renin |
1652 | Th1148 | Aliskiren | N.A. Full view | 0 | IIa | Metabolic | Amturnide | Novartis Pharmaceuticals Corporation | Tablets (aliskiren/ amlodipine/ HCTZ): 150/5/12.5, 300/5/12.5, 300/5/25, 300/10/12.5, 300/10/25 mg. | Oral route | Renin inhibitor | Renin |
1653 | Th1149 | Ragweed Pollen Extract | N.A. Full view | 0 | IIIa | Immunological | Ragwitek | Merck Sharp & Dohme | Tablets | Oral route | N.A. | N.A. |